ERAAs for menopause treatment: Welcome the 'designer estrogens'

Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cleveland Clinic journal of medicine 2017-06, Vol.84 (6), p.463-470
Hauptverfasser:	Hirsch, Heather D, Shih, Elim, Thacker, Holly L
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone Diseases, Metabolic - drug therapy Breast Neoplasms - drug therapy Drug Therapy, Combination Estrogens - pharmacology Female Hot Flashes - drug therapy Humans Menopause - physiology Selective Estrogen Receptor Modulators - pharmacology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns.
ISSN:	0891-1150 1939-2869
DOI:	10.3949/ccjm.84a.15140